DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on January 13, 2006; DOI: 10.1124/dmd.105.008292


0090-9556/06/3404-563-569$20.00
DMD 34:563-569, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.008292v1
dmd.105.008292v2
34/4/563    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaedigk, A.
Right arrow Articles by Leeder, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaedigk, A.
Right arrow Articles by Leeder, J. S.

CYP2D6*36 GENE ARRANGEMENTS WITHIN THE CYP2D6 LOCUS: ASSOCIATION OF CYP2D6*36 WITH POOR METABOLIZER STATUS

Andrea Gaedigk, L. DiAnne Bradford, Sarah W. Alander, and J. Steven Leeder

Section of Developmental Pharmacology & Experimental Therapeutics, The Children's Mercy Hospital and Clinics, Kansas City, Missouri (A.G., S.W.A., J.S.L.); and Morehouse School of Medicine, Atlanta, Georgia (L.D.B.)

Unexplained cases of CYP2D6 genotype/phenotype discordance continue to be discovered. In previous studies, several African Americans with a poor metabolizer phenotype carried the reduced function CYP2D6*10 allele in combination with a nonfunctional allele. We pursued the possibility that these alleles harbor either a known sequence variation (i.e., CYP2D6*36 carrying a gene conversion in exon 9 along the CYP2D6*10-defining 100C>T single-nucleotide polymorphism) or novel sequences variation(s). Discordant cases were evaluated by long-range polymerase chain reaction (PCR) to test for gene rearrangement events, and a 6.6-kilobase pair PCR product encompassing the CYP2D6 gene was cloned and entirely sequenced. Thereafter, allele frequencies were determined in different study populations comprising whites, African Americans, and Asians. Analyses covering the CYP2D7 to 2D6 gene region established that CYP2D6*36 did not only exist as a gene duplication (CYP2D6*36x2) or in tandem with *10 (CYP2D6*36+*10), as previously reported, but also by itself. This "single" CYP2D6*36 allele was found in nine African Americans and one Asian, but was absent in the whites tested. Ultimately, the presence of CYP2D6*36 resolved genotype/phenotype discordance in three cases. We also discovered an exon 9 conversion-positive CYP2D6*4 gene in a duplication arrangement (CYP2D6*4Nx2) and a CYP2D6*4 allele lacking 100C>T (CYP2D6*4M) in two white subjects. The discovery of an allele that carries only one CYP2D6*36 gene copy provides unequivocal evidence that both CYP2D6*36 and *36x2 are associated with a poor metabolizer phenotype. Given a combined frequency of between 0.5 and 3% in African Americans and Asians, genotyping for CYP2D6*36 should improve the accuracy of genotype-based phenotype prediction in these populations.


Address correspondence to: Dr. Andrea Gaedigk, Section of Developmental Pharmacology and Experimental Therapeutics, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108. E-mail: agaedigk{at}cmh.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
W.-Y. Zhang, Y.-B. Tu, R. L. Haining, and A.-M. Yu
Expression and Functional Analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 Isozymes
Drug Metab. Dispos., January 1, 2009; 37(1): 1 - 4.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. Sakuyama, T. Sasaki, S. Ujiie, K. Obata, M. Mizugaki, M. Ishikawa, and M. Hiratsuka
Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57)
Drug Metab. Dispos., December 1, 2008; 36(12): 2460 - 2467.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
J. S. Leeder, R. E. Pearce, A. Gaedigk, A. Modak, and D. I. Rosen
Evaluation of a [13C]-Dextromethorphan Breath Test to Assess CYP2D6 Phenotype
J. Clin. Pharmacol., September 1, 2008; 48(9): 1041 - 1051.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
J. de Leon, N. B. Sandson, and K. L. Cozza
A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part II
Psychosomatics, July 1, 2008; 49(4): 347 - 361.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.